Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection
Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection
The purpose of this study was to evaluate the safety and pharmacokinetics (PK) of raltegravir
 (RAL) when given to HIV-1-exposed, normal birth weight newborn infants at risk of acquiring
 HIV-1 infection. (PK is the study of the time course of absorption, distribution, metabolism,
 and excretion of drugs in the body.) The primary goal of this study was to determine a dose
 of RAL that was safe and met the PK targets for infants when administered during the first 6
 weeks of life in addition to standard of care antiretroviral (ARV) agents for prevention of
 perinatal transmission.
This is a Phase I multi-center, open label, non-comparative study to evaluate the safety and
 PK of RAL administered to HIV-1-exposed full-term (≥37 weeks of gestation) infants when
 administered during the first 6 weeks of life in addition to the infants' standard HIV-1 ARV
 prophylaxis.

 IMPAACT P1097 (NCT01828073) demonstrated that RAL crossed the placenta from mother to fetus
 after maternal dosing during pregnancy and RAL was slowly eliminated by the newborn after
 birth. Therefore, for P1110, within each cohort, infants were stratified into the "RAL-naive"
 or "RAL-exposed" groups depending on infants' in utero exposure to maternal RAL. The study
 stratification with respect to in utero RAL exposure allowed for adjustment of the initial
 RAL dosing (i.e. timing and/or dose size).

 Study participants were enrolled in two sequential cohorts with the following actual dosing
 of RAL in addition to their local standard of care ARV agents for prevention of perinatal
 transmission. PK and safety data from Cohort 1 (two single doses) provided information for
 the starting dosing for Cohort 2 (daily dosing through 6 weeks of life).

 Cohort 1: Two single RAL doses: first dose within 48 hours of birth and second dose at 7-10
 days of life.

 -  Cohort 1, RAL-naive: 3 or 2 mg/kg within 48 hours of birth and 3 mg/kg at 7-10 days of
 life. (P1110 V1.0 Clarification Memorandum #3, dated January 15, 2015, adjusted the
 first dose from 3 mg/kg to 2 mg/kg based on available PK data.)

 -  Cohort 1, RAL-exposed: 1.5 mg/kg within 48 hours of birth and 3 mg/kg at 7-10 days of
 life.

 Cohort 2: Daily RAL dosing through 6 weeks of life.

 -  Cohort 2, RAL-naive: Daily dosing through 6 weeks of life with initial RAL dosing within
 48 hours of birth: 1.5 mg/kg once daily during Days 1-7 of life, 3.0 mg/kg twice daily
 during Days 8-28 of life, and 6.0 mg/kg twice daily during Days 29-42 of life.

 -  Cohort 2, RAL-exposed: Daily dosing through 6 weeks of life with initial RAL dosing
 between 12-60 hours of birth: 1.5 mg/kg once daily during Days 1-7 of life, 3.0 mg/kg
 twice daily during Days 8-28 of life, and 6.0 mg/kg twice daily during Days 29-42 of
 life.

 Target enrollment was approximately 50 infants and their mothers in order to have a minimum
 of 12 and 20 PK evaluable infants in Cohorts 1 and 2, respectively. Cohort 1 and Cohort 2
 RAL-naive infants (and their mothers) were enrolled under protocol Version 1.0. Cohort 2
 RAL-exposed infants (and their mothers) were enrolled under protocol Version 2.0.

 Infants and their mothers were enrolled within 48 and within 60 hours of delivery under
 protocol Versions 1.0 and 2.0, respectively. Infants were followed through 24 weeks of life
 and their mothers were followed until discharge from the labor and delivery unit.

 Infant PK samples were collected as follows:

 Cohort 1:

 -  Dose #1 (within 48 hours of birth) intensive PK sampling: Within 30 min pre-dose, and
 1-2 hours post-dose, 4-8 hours post-dose, 12 (±1) hours post-dose, and 24 (±1) hours
 post-dose.

 -  One random PK sample at 3-4 days of life.

 -  Dose #2 (7-10 days of life) limited PK sampling: Within 30 min pre-dose, and 1-2 hours
 post-dose and 24 (±1) hours post-dose.

 Cohort 2:

 -  Initial dose (within 48 and 12-60 hours of birth for RAL-naive and RAL-exposed infants,
 respectively) intensive PK sampling: Within 1 hour pre-dose, and 1-2 hours, 6-10 hours,
 20-24 hours post-dose.

 -  PK sampling for second dose: 3-6 hours post-dose.

 -  PK sampling at 6-9 days of life: Within 1 hour pre-dose of initiating 3mg/kg twice
 daily.

 -  Intensive PK sampling at 15-18 days of life: Within 1 hour pre-dose, and 1-2 hours
 post-dose, 4-6 hours post-dose, and 8-12 hours post-dose.

 -  PK sampling at 28-32 days of life: Within 1 hour pre-dose of initiating 6 mg/kg twice
 daily.

 -  PK sampling at 33-42 days of life done at Week 5-6 visit: Within 1 hour pre-dose, and
 3-6 hours post-dose.

 Protocol defined infant safety evaluations were done at:

 Cohort 1: Entry, 3-4 days of life, 7-10 days of life, 2 weeks of life, 6 weeks of life and 24
 weeks of life.

 Cohort 2: Entry, 2-4 days of life, 6-9 days of life, 15-18 days of life, 28-32 days of life,
 5-6 weeks of life, 8-10 weeks of life and 24 weeks of life.

 Infant safety data included death, signs/symptoms, diagnoses and laboratory test results.
 Laboratory test results included results from evaluations specified in the protocol and
 evaluations done as part of the infant's clinical care which the sites considered relevant.

 PK evaluable infants were those determined by the protocol pharmacologist to have PK results
 which provide analyzable data on the primary PK parameters of interest. Infants who were PK
 unevaluable were replaced for PK analysis but continued with the study safety follow-up
 visits.

 Infants were evaluable for safety analysis if they received at least one dose of RAL. The
 safety analyses were based on data from all safety evaluable infants, regardless of whether
 they were evaluable for PK analysis.

 The study initially opened accrual to Cohort 1 RAL-naive group. The PK and safety data from
 IMPAACT P1110 Cohort 1 RAL-naive group and from IMPAACT P1097 were used to determine the
 starting dose for the Cohort 1 RAL-exposed group. Opening accrual to the Cohort 2 RAL-naive
 group was contingent upon infants enrolled in Cohort 1 RAL-naive and RAL-exposed groups
 successfully meeting safety criteria and providing adequate PK data to determine a regimen to
 be tested for daily dosing through 6 weeks of life for the Cohort 2 RAL-naive group. The
 initial dosing regimen for the Cohort 2 RAL-naive group was determined using population PK
 modeling and simulations incorporating IMPAACT P1110 Cohort 1 data, along with data from the
 following IMPAACT studies: P1097, P1066 (NCT00485264) (Cohorts IV and V) and P1026s
 (NCT00042289). Since the PK results of Cohort 1 RAL-naive and exposed groups were similar
 except in the first 1-2 days of life and P1097 Cohort 1 results suggested that maternal RAL
 readily crosses the placenta and results to washout RAL exposure in neonates, Cohort 2
 RAL-exposed group was determined to receive the same dose of RAL as Cohort 2 RAL-naive group,
 except the initial dose for RAL-exposed was delayed to within 12 to 60 hours of life.
Maternal Inclusion Criteria:

 -  Mother is living with HIV and either i) known to have HIV diagnosis prior to labor
 (testing obtained and designated per local SOC in the medical record and either on or
 recently started CART prior to delivery) or ii) identified as having HIV diagnosis at
 the time of labor or in the immediate postpartum period. More information on this
 criterion can be found in the protocol.

 -  Risk of mothers transmitting HIV to their infants:

 -  Cohort 1 and Cohort 2 (RAL-naive): Mother living with HIV is at "high risk" of
 transmitting HIV to infant as evidenced by any of the following: Mother has not
 received any ARV therapy during the current pregnancy prior to the onset of labor
 and delivery; HIV RNA level greater than 1000 copies/mL within 4 weeks (28 days)
 prior to delivery; receipt of ARV for less than 4 weeks (28 days) before
 delivery; on ARVs for 4 weeks or longer but has not taken any ARV for more than 7
 days prior to delivery; or mother has documented drug resistant virus to at least
 one class of ARV drugs.

 -  Cohort 2 RAL-exposed: there was no requirement that the mother living with HIV is
 at "high-risk" of transmitting HIV to her infant.

 -  Maternal written informed consent for study participation

 Maternal Exclusion Criteria:

 -  Known maternal-fetal blood group incompatibility as evidenced by the presence of an
 unexpected clinically significant maternal red cell antibody that is known to be
 capable of causing hemolytic disease of the fetus/newborn

 -  Mother will be receiving RAL as part of her combination antiretroviral (cART) regimen
 after delivery and intending to breastfeed her infant

 -  For Cohort 1 and Cohort 2 RAL-naive groups:

 -  Cohort 1 RAL-naive: Mother who received RAL prior to and through delivery unless
 last RAL dosing during prenatal period was >7 days prior to delivery

 -  Cohort 2 RAL-naive: Mother who received RAL prior to and through delivery

 Infant Inclusion Criteria:

 -  Age at enrollment (Note: The full-term infants were HIV-exposed and may have received
 standard of care ARV prophylaxis/treatment before enrollment):

 -  Cohort 1 and Cohort 2 RAL-naive: Aged 48 hours or less.

 -  Cohort 2 RAL-exposed: Aged 60 hours or less.

 -  Infant gestational age at birth at least 37 weeks

 -  No known severe congenital malformation or other medical condition not compatible with
 life or that would interfere with study participation or interpretation, as judged by
 the examining clinician

 -  Birth weight at least 2 kg

 -  Able to take oral medications

 -  Parent or legal guardian able and willing to provide signed informed consent

 -  For Cohort 1 and Cohort 2 RAL-exposed groups:

 -  Cohort 1 RAL-exposed: Infants born to mothers who received RAL during pregnancy
 with last dose taken within 7 days before delivery.

 -  Cohort 2 RAL-exposed: Infants born to a mother who received at least one dose of
 RAL within 2 to 24 hours prior to delivery.

 Infant Exclusion Criteria:

 -  Infant with bilirubin exceeding the American Academy of Pediatrics guidelines for
 phototherapy, using the infant's gestational age and risk factors as described in the
 protocol.

 -  Clinical evidence of renal disease such as edema, ascites, or encephalopathy.

 -  Receipt of disallowed medications (phenytoin, phenobarbital, or rifampin).